Specialty Pharmacy Times
Generic Pharmacy Report
Directions in Pharmacy
Health Care Reform
Acute Coronary Syndrome
Medication Therapy Management
Type 2 Diabetes
Vitamins and Supplements
News & Views
Compounding in the Kitchen
Piller of the Community
Focus on Current Thinking
The Reinvented Pharmacist
Pharmacists United for Truth and Transparency
For the Record
Interactive Tools: Mapped!
OTC Guide App
PharmacyTimes Augmented Reality
Videos | Page 3
Why Should Hydrocodone Combination Products Be Categorized as CII Drugs?
Mary Lynn McPherson, PharmD, explains why hydrocodone combination products should no longer be categorized as Schedule III drugs.
Codeine and Rescheduling Hydrocodone Combination Products
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II could lead to increased prescription of codeine, a much “sloppier” drug that could create problems for patients.
Rescheduling Hydrocodone Combination Products Will Lead to More Responsible Use
Mary Lynn McPherson, PharmD, argues that rescheduling hydrocodone combination products will lead to more responsible prescribing of the drugs and monitoring of their use.
Rescheduling Hydrocodone Combination Products: Lessons from New York State
Jeff Fudin, PharmD, FCCP, discusses the effect of rescheduling hydrocodone combination products as CII in New York State on prescription of other opioids, including oxycodone.
How Rescheduling Hydrocodone Combination Products Will Reduce Abuse
Mary Lynn McPherson, PharmD, explains how rescheduling hydrocodone combination products as Schedule II drugs will help reduce levels of abuse.
Abuse Liability of Hydrocodone Combination Products
Jeff Fudin, PharmD, FCCP, argues that studies comparing the abuse liability of hydrocodone combination products with that of other opioids have produced conflicting results.
Rationale for Categorizing Hydrocodone Combination Products as Schedule III
Mary Lynn McPherson, PharmD, discusses why hydrocodone combination products were categorized as Schedule III in the first place.
Will Rescheduling Hydrocodone Combination Products Actually Reduce Abuse?
Jeff Fudin, PharmD, FCCP, argues that categorizing hydrocodone combination products as Schedule II drugs is unlikely to reduce abuse of the medications.
Effect of Beta-Blockers on Mortality after Myocardial Infarction in Adults with COPD
Researchers discuss their study of COPD patients who have experienced a first myocardial infarction and the impact of beta-blocker therapy on mortality.
Marine Compound Discovery Shows Promise of Improved Drug Treatment for COPD Patients
University of Florida pharmacy researchers have isolated a compound from blue-green algae that may inhibit the progression of pulmonary disease.
American Journal of Managed Care
American Journal of Pharmacy Benefits
Physician's Money Digest
Specialty Pharmacy Times
Terms & Conditions
666 Plainsboro Road
Plainsboro, NJ 08536
Copyright HCPLive 2006-2013
Intellisphere, LLC. All Rights Reserved.